Syapse, a San Francisco, CA, and New York-based leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, has announced the closing of a $35 million growth funding.
The investment is led by an affiliate of Innovatus Capital Partners, LLC (Innovatus), with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.
The funding intends used to expand its focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer.
Company: Syapse, Inc.
Funding Month: July 2022
Lead Investors: affiliate of Innovatus Capital Partners, LLC
Additional Investors: Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital
Company Website: https://syapse.com/
Software Category: Advancing real-world care
About the Company: Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care. By marrying clinical expertise with smart technologies, we transform data into evidence—and then into an experience—in collaboration with our network of partners, who are committed to improving patients’ lives through community health systems. Together, we connect comprehensive patient insights to our network, to empower our partners in driving real impact and improving access to high-quality care.